Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA versus DAS for advanced or metastatic prostate cancer
ISRCTN13255144Phase 2Completed
- Sponsor
- United States Department of Health and Human Services
- Start
- Jan 2001
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of dexamethasone, aspirin, diethylstilbestrol and ranitidine in prostate cancer (PCa) and prostate adenocarcinoma (2 arms), sponsored by United States Department of Health and Human Services. Primary endpoints: PSA response rate and Quality of life. Started Jan 2001; status: completed.
02
Drugs
dexamethasoneaspirindiethylstilbestrolranitidine
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on ISRCTN13255144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13255144.